2015/7/29 17:55


AsiaNet 61331(0976)


Logo -








Nutraceutix, +1-800-548-3222,

Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism


REDMOND, Wash., July 29, 2015 /PRN=KYODO JBN/ --

    A German Diabetes Center clinical study found that daily ingestion of

Nutraceutix's L. reuteri probiotic enriches human gut microbiota and modifies

gut production of protein factors that increase insulin secretion.  The study

involved daily administration of Nutraceutix's L. reuteri strain (ATCC strain

SD-5865) in tablets using the patented BIO-tract(R) delivery technology that

protects live probiotics from damage by stomach acid on their way to the

intestinal tract.

    Logo -

    The randomized, double-blind, placebo-controlled study compared secretion

of insulin, C-peptide, and proglucagon-derived peptides and pancreatic

beta-cell function in glucose-stimulated non-diabetic participants to measure

incretin effect.  Participants took L. reuteri tablets or placebo tablets daily

over a four-week period.  People taking the L. reuteri had increased

glucose-stimulated insulin secretion by 49%, C-peptide secretion by 55%, GLP-1

release by 76%, GLP-2 release by 43%, and altered beta-cell function relative

to people taking the placebo.  In a related presentation before the American

Diabetes Association, the study's primary researcher concluded, "probiotic

treatment may improve incretin-mediated beta-cell function, which could be

beneficial for the treatment of glucose intolerance or overt type 2 diabetes."

    Detailed gut microbiota composition analysis of the study participants was

done before and after the study.  After the study, all those taking L. reuteri

BIO-tract tablets had detectable L. reuteri in their stool samples, while those

tested from the placebo group did not.  No participants reported adverse


    The study article was published online along with supplementary data, at

the American Diabetes Association(R) (ADA) Diabetes Care(R) website in June

2015, doi: 10.2337/dc14-2690.  The referenced presentation was made at the 72nd

Scientific Sessions of the ADA, Philadelphia, PA, in June 2012.  A webcast of

the presentation can be found at the website.  

    Nutraceutix is a Registered GMP contract manufacturer of probiotics in bulk

powder, and in standard and advanced capsule and tablet forms.  Nutraceutix's

BIO-tract technology is protected by U.S. Patent Nos. 8,540,980 and 8,007,777,

and over 30 international patents.

    Disclaimer:  BIO-tract is a registered trademark of Nutraceutix.  

Nutraceutix is not affiliated with the American Diabetes Association.  The

American Diabetes Association(R) and Diabetes Care(R) are trademarks owned by

their respective holders.  Use of them does not imply affiliation or

endorsement by them.

SOURCE  Nutraceutix

    CONTACT: Nutraceutix, +1-800-548-3222,